<DOC>
	<DOC>NCT01596335</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of TA-650 in comparison with a control drug Polyethylene Glycol-treated Human Immunoglobulin (VGIH) in patients with Kawasaki disease refractory to initial therapy with Intravenous Immunoglobulin (IVIG). The pharmacokinetics of TA-650 is also examined.</brief_summary>
	<brief_title>Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease</brief_title>
	<detailed_description />
	<mesh_term>Mucocutaneous Lymph Node Syndrome</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho(D) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patients diagnosed with Kawasaki disease (incipient cases only) with 5 or more of the 6 major symptoms of Kawasaki disease. Patients refractory to initial IVIG therapy (a single administration at 2 g per kg body weight). Patients with a fever of 37.5ºC or higher axillary temperature at the time of enrollment. Patients to whom the study drug can be administered by day 8 of disease. Patients who have received vaccination with Bacille CalmetteGuérin (BCG) vaccine within 6 months before the enrollment. Patients with a complication, or a history within 6 months before the enrollment of, serious infections requiring hospitalization. Patients with a complication, or a history within 6 months before the enrollment of, opportunistic infections. Patients complicated with active tuberculosis, active hepatitis B or C, or patients confirmed to be hepatitis B virus carriers or a history of hepatitis B. Patients confirmed to have HIV infection, or patients with a family history of HIV infection. Patients who have a history of receiving treatment with infliximab or other biological products. Patients who had participated in another clinical study and had received a study drug within 12 weeks before giving consent.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Infliximab</keyword>
	<keyword>REMICADE</keyword>
	<keyword>TA-650</keyword>
	<keyword>intravenous immunoglobulin</keyword>
	<keyword>Kawasaki disease</keyword>
	<keyword>IVIG</keyword>
</DOC>